Released Mar 14, 2024, before the open
10-K filed Mar 14, 2024, 74 days after period end · 0001558370-24-003161
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.49M$10.49M derived+21.7% vs Q4 2022+1.4% vs Q3 2023
Net Income-$6.04M-$6.04M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,615,000N/M
Operating Cash Flowderived$3,595,000N/M
Free Cash Flowderived$3,345,000N/M
Margins · derived
Operating margin-53.5%−24.6 pt vs Q4 2022
Net margin-57.6%−14.2 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $10.49M | $8.62M | $8.55M | $19.50M |
| Net Income | -$6.04M | -$3.74M | -$6.67M | $397.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR